The invention concerns the use for treating and cleaning the eye and its appendages of aqueous ionic solutions obtained from sea water whereof the ionic composition is qualitatively that of sea water and quantitatively such that their ph ranges between 4 and 9, preferably between 7 and 8 and their osmolality ranges between 150 and 700, preferably between 250 and 350 mOsm/kg.
|
1. An aqueous ionic solution comprising of:
a) from 1300 to 1500 mg/l of Na+,
b) from 4500 to 6500 mg/l of K+,
c) from 50 to 1300 mg/l of Mg++,
d) from 20 to 350 mg/l of ca++,
e) from 4000 to 6000 mg/l of Cl−,
g) a ph of from 4-9, and
h) an osmolality of from 150-700 mOsm/kg.
6. An aqueous ionic solution according to
a) the Na+ concentration is about 680 mg/l,
b) the K+ concentration is about 5820 mg/l,
c) the Mg++ concentration is about 130 mg/l,
d) the Ca++ concentration is about 55 mg/l, and
f) the Cl− concentration is about 4850 mg/l.
7. A method for rinsing an eye of a subject in need thereof comprising administering drops of the aqueous ionic solution of
|
|||||||||||||||||||
This is a continuation of application Ser. No. 10/169,284 filed Jan. 29, 2003 now abandoned; which claims benefit to PCT/FR 00/03709 filed Dec. 28, 2000; which claims priority to French Patent 99/16,814 filed Dec. 31, 1999.
The invention relates to aqueous ionic solutions of the type obtained in particular from seawater and their uses in particular in ophthalmology.
Some of these aqueous ionic solutions are novel. The invention consequently relates to them as novel industrial products.
Apart from the latter, aqueous ionic solutions obtained from seawater are known.
It has already been proposed to apply them in the prevention, cleaning and treatment of the respiratory tracts, the buccal cavities, the skin and the gynecological mucous membranes.
These indeed appeared to be the only applications which could be envisaged by persons skilled in the art.
However, the applicant company has had the merit,
The subject of the invention is therefore the use, for treating and cleaning the eye and its appendages, of the aqueous ionic solutions obtained from seawater and whose ionic composition, pH and osmolality have been consequently adjusted.
From the qualitative point of view, the ionic composition of the solutions used in accordance with the invention is that of seawater.
By way of illustration, the composition of seawater as it appears on page F 163 of the manual “Handbook of Chemistry and Physics” 63rd edition, 1982-1983, CRC PRESS, is indicated in the table below.
TABLE
Element
Quantity (p.p.m.)
Cl
18.980
Na
10.561
Mg
1.272
S
884
Ca
400
K
380
Br
65
C (inorganic)
28
Sr
13
(SiO2)
0.01-7.0
B
4.6
Si
0.02-4.0
C (organic)
1.2-3.0
Al
0.16-1.9
F
1.4
N (as nitrate)
0.001-0.7
N (as organic nitrogen)
0.03-0.2
Rb
0.2
Li
0.1
P (as phosphate)
>0.001-0.10
Ba
0.05
I
0.05
N (as nitrite)
0.0001-0.05
N (as ammonia)
>0.005-0.05
As (as arsenic)
0.003-0.024
Fe
0.002-0.02
P (as organic phosphorus)
0.016
Zn
0.005-0.014
Cu
0.001-0.09
Mn
0.001-0.01
Pb
0.004-0.005
Se
0.004
Sn
0.003
Cs
0.002 (approximately)
U
0.00015-0.0016
Mo
0.0003-0.002
Ga
0.0005
Ni
0.0001-0.0005
Th
<0.0005
Ce
0.0004
V
0.0003
La
0.0003
Y
0.0003
Hg
0.00003
Ag
0.00015-0.0003
Bi
0.0002
Co
0.0001
Sc
0.00004
Au
0.000004-0.000008
Fe (as a true solution)
<10−9
Ra
2.10−11-3.10−10
Ge
Present
Ti
Present
W
Present
Cd
Present in marine organisms
Cr
Present in marine organisms
Ti
Present in marine organisms
Sb
Present in marine organisms
Zr
Present in marine organisms
Pt
Present in marine organisms
On the same page of the same manual, it is specified that the pH of seawater is 8-9.
It is moreover known (IFREMER, Department of Coastal Environment and Management of the Marine Environment) that the osmolality of seawater is >1 000 mOsm/kg.
From the quantitative point of view, the ionic composition of the solutions in question, obtained from seawater, is chosen such that their pH is from 4 to 9, preferably from 7 to 8, and that their osmolality is from 150 to 700, preferably from 250 to 350 mOsm/kg.
Among the solutions which have given particularly encouraging results in the use in accordance with the invention, there may be mentioned:
The aqueous ionic solutions in accordance with the invention, which constitute novel industrial products and which are in particular obtained from seawater, are characterized by:
In the case of seawater, the corresponding values are exemplified by the ranges reflecting the results of 134 measurements carried out on seawater collected off Saint-Malo from August 1998 to July 1999, namely:
pH
7.70 to 8.30
osmolality
>1 000
mOsm/kg
[Na+]
10 500-11 500
mg/l
[K+]
365-420
mg/l
[Mg++]
1 200-1 450
mg/l
[Ca++]
380-435
g/l
[Cl−]
18 900-20 500
mg/l
The novel aqueous ionic solutions in accordance with the invention are particularly appropriate for treating and cleaning the eye and its appendages.
However, they can also be used in the treatment and cleaning of the respiratory tracts, the buccal cavities, the skin and the mucous membranes, in particular gynecological mucous membranes, optionally after adjusting the pH and the osmolality as necessary.
The aqueous ionic solutions in accordance with the invention as defined above, when they are used for treating and cleaning the eye and its appendages, are remarkable in that
The latter advantage is of great importance.
Indeed, the preservatives present in most medicaments for the eye are considered harmful for the cornea.
For the preparation of the aqueous ionic solution in accordance with the invention, seawater was used which was taken off Saint-Malo and collected at a depth of 5 to 10 meters in a zone with strong movements of current; this water is characterized by a salt content greater than 32 g/l; it is naturally rich in calcium, magnesium and trace elements.
This water is subjected to selective electrodialysis; in a first instance, only sodium chloride is removed in order to reach the desired osmolality, then the ionic concentrations are adjusted depending on the therapeutic use; the desired pH is preferably obtained by exchanging the Na+ ions against protons.
Selective electrodialysis may be carried out with an EUR 6B type apparatus marketed by the company EURODIA Industrie SA under the trademark EURODIA.
The various stages of the selective electrodialysis corresponding to the adjustment of each of the different parameters (pH, osmolality, ion concentration) are carried out in a known manner.
The characteristics of the solution examined are as follows:
pH
7.45
osmolality
309
mOsm/kg
[Na+]
680
mg/l
[K+]
5 818
mg/l
[Mg++]
128
mg/l
[Ca++]
54
mg/l
[Cl−]
4 850
mg/l
It was with the aid of a test derived from the Draize test that it was shown that this solution was not very irritant toward the eye and, in any case, less irritant than physiological serum or physiological saline.
The Draize test makes it possible to evaluate eye irritation after multiple applications; it can be carried out on the eye of albino rabbits.
The reference solution used in this test consists, as indicated above, of physiological saline, that is to say a solution of sodium chloride (0.9% NaCl); physiological saline is traditionally used to rinse the eyes in the event of an accidental chemical spillage, to clean the eyes of unweaned babies and also as solvent for artificial tears, as collyrium or as ophthalmic washing solution; it is the reference solution in ophthalmology for the French Agency for the Safety of Health Products.
According to the Draize test, 12 albino rabbits are divided into two groups (a reference group and a group for the test solution).
There are administered, six times consecutively at intervals of 1 hour into the conjunctival cul-de-sac of the right eye
The treated eyes of the rabbits are examined using a slit lamp (Slit lamp AIT-20, Topcon, Topcon France—F-92300 Levallois-Perret), before instillation, and then 1 hour after the 1st and 6th instillations, respectively, and then 1, 2 and 3 days after the sixth instillation.
The effects produced on the conjunctiva, the iris and the cornea are observed.
As regards the conjunctiva, the following were noted:
For the evaluation of the effect on the conjunctiva, there is selected the figure obtained by applying the formula:
(a+b+c)×2.
In the case of the iris, there is awarded a score ranging from 0 to 2, the score 0 corresponding to a normal iris and the score 2 corresponding to an iris exhibiting no reaction to light but exhibiting, on the other hand, hemorrhages and severe impairments.
For the evaluation of the effect on the iris, there is chosen the figure given by the formula:
(d)×5.
Finally, as regards the cornea, there are evaluated, on the one hand, the intensity (e) of the opaqueness, knowing that the score 0 is awarded for the absence of opaqueness and the score 4 for complete corneal opaqueness with an invisible iris, and, on the other hand, the area of opaqueness (f), the scores ranging from 0 to 4, the latter score corresponding to an opacification of more than ¾ of the total area.
For the evaluation, there is selected the value given by the formula:
e×f×5.
The sum of the values obtained for the conjunctiva, the iris and the cornea, at each measurement and for each animal, represents the individual ocular irritation index (IOI) which is 110 maximum.
The arithmetic mean of the values found for the 6 rabbits represents the mean ocular irritation index (MOI).
The maximum ocular irritation index (MOI max) is the maximum individual value obtained at each measurement.
The results obtained with the solution in accordance with the invention and with physiological saline are assembled in tables I and II which follow and in which:
TABLE I
(solution in accordance with the invention)
Day 1/0
Day 1/1
Day 1/6
Day 2
Day 3
Day 4
MOI
0.00
0.67
0.00
0.00
0.00
0.00
MOI max
0
4
0
0
0
0
TABLE II
(physiological saline)
Day 1/0
Day 1/1
Day 1/6
Day 2
Day 3
Day 4
MOI
0.00
0.00
1.00
0.33
0.67
0.00
MOI max
0
0
4
2
2
0
On comparing these values, it is observed that the superiority of the solution in accordance with the invention manifests itself from the measurement made on Day 1/6 and becomes beneficial on Days 2 and 3, which means that the solution defined above is particularly beneficial for long-term treatments and for those requiring multiple applications.
This being the case, and from a general point of view, the products, in particular the ophthalmic products, prepared using the aqueous ionic solutions in accordance with the invention or more generally any aqueous ionic solutions obtained from seawater may be provided, for example, in the form of lotions intended for washing the eye, in the form of collyria, ophthalmological gels, or to replace the water in ocular inserts.
The composition of such a lotion may be as follows:
aqueous ionic solution:
qsp 100%
salicylic acid:
0.1%
distilled water of hamamelis
0.4%
The lotions in question may be administered using, more preferably, devices of the type according to the French patent application filed in the name of the applicant on 13 Oct. 1999 under No. 99 12782 under the title “Device for washing and bathing the eye”.
By way of example, it is reported that it is possible to carry out 2 or 3 eye washes or baths per day.
Yvin, Jean-Claude, Leroy, Didier, Halley, Benedicte Marie Dominique
| Patent | Priority | Assignee | Title |
| Patent | Priority | Assignee | Title |
| 4581226, | Apr 07 1983 | Method of treating sensitive animal tissue with a specially processed seawater solution | |
| 6451352, | Jun 29 1998 | LABORATOIRE DE LA MER | Use of iso-osmotic saline solutions, method for preparing same and medicine based on said solutions |
| 6709680, | Jun 29 1998 | LABORATOIRE DE LA MER | Use of iso-osmotic saline solutions, method for preparing same and cerumenolytic medicines based on said solutions |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| May 23 2005 | Laboratories de la Mer | (assignment on the face of the patent) | / | |||
| Aug 29 2008 | Laboratoires Goemar | LABORATOIRE DE LA MER | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 021707 | /0237 |
| Date | Maintenance Fee Events |
| Nov 29 2013 | REM: Maintenance Fee Reminder Mailed. |
| Apr 20 2014 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
| Date | Maintenance Schedule |
| Apr 20 2013 | 4 years fee payment window open |
| Oct 20 2013 | 6 months grace period start (w surcharge) |
| Apr 20 2014 | patent expiry (for year 4) |
| Apr 20 2016 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Apr 20 2017 | 8 years fee payment window open |
| Oct 20 2017 | 6 months grace period start (w surcharge) |
| Apr 20 2018 | patent expiry (for year 8) |
| Apr 20 2020 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Apr 20 2021 | 12 years fee payment window open |
| Oct 20 2021 | 6 months grace period start (w surcharge) |
| Apr 20 2022 | patent expiry (for year 12) |
| Apr 20 2024 | 2 years to revive unintentionally abandoned end. (for year 12) |